MedTrace Logo

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

NCT00123890 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2011-03-29

No results posted yet for this study

Summary

The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.

Conditions

  • HIV Infection

Interventions

DRUG

GW873140

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, Ph.D. · GlaxoSmithKline

Study Design

Purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States
  • Belgium
  • Canada
  • Denmark
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123890 on ClinicalTrials.gov